198 related articles for article (PubMed ID: 32279446)
1. Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2.
Kudo M; Galle PR; Llovet JM; Finn RS; Vogel A; Motomura K; Assenat E; Merle P; Brandi G; Daniele B; Okusaka T; Tomášek J; Borg C; Dadduzio V; Morimoto M; Pracht M; Jen MH; Drove Ubreva N; Widau RC; Shinozaki K; Yoshikawa R; Zhu AX
Liver Int; 2020 Aug; 40(8):2008-2020. PubMed ID: 32279446
[TBL] [Abstract][Full Text] [Related]
2. Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial.
Kudo M; Okusaka T; Motomura K; Ohno I; Morimoto M; Seo S; Wada Y; Sato S; Yamashita T; Furukawa M; Aramaki T; Nadano S; Ohkawa K; Fujii H; Kudo T; Furuse J; Takai H; Homma G; Yoshikawa R; Zhu AX
J Gastroenterol; 2020 Jun; 55(6):627-639. PubMed ID: 32107609
[TBL] [Abstract][Full Text] [Related]
3. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Pracht M; Lim HY; Rau KM; Motomura K; Ohno I; Merle P; Daniele B; Shin DB; Gerken G; Borg C; Hiriart JB; Okusaka T; Morimoto M; Hsu Y; Abada PB; Kudo M;
Lancet Oncol; 2019 Feb; 20(2):282-296. PubMed ID: 30665869
[TBL] [Abstract][Full Text] [Related]
4. Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials.
Zhu AX; Nipp RD; Finn RS; Galle PR; Llovet JM; Blanc JF; Okusaka T; Chau I; Cella D; Girvan A; Gable J; Bowman L; Wang C; Hsu Y; Abada PB; Kudo M
ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32817068
[TBL] [Abstract][Full Text] [Related]
5. Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison.
Trojan J; Mollon P; Daniele B; Marteau F; Martín L; Li Y; Xu Q; Piscaglia F; Zaucha R; Sarker D; Lim HY; Venerito M
Adv Ther; 2021 May; 38(5):2472-2490. PubMed ID: 33822328
[TBL] [Abstract][Full Text] [Related]
6. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study.
Chau I; Peck-Radosavljevic M; Borg C; Malfertheiner P; Seitz JF; Park JO; Ryoo BY; Yen CJ; Kudo M; Poon R; Pastorelli D; Blanc JF; Chung HC; Baron AD; Okusaka T; Bowman L; Cui ZL; Girvan AC; Abada PB; Yang L; Zhu AX
Eur J Cancer; 2017 Aug; 81():17-25. PubMed ID: 28591675
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials.
Llovet JM; Singal AG; Villanueva A; Finn RS; Kudo M; Galle PR; Ikeda M; Callies S; McGrath LM; Wang C; Abada P; Widau RC; Gonzalez-Gugel E; Zhu AX
Clin Cancer Res; 2022 Jun; 28(11):2297-2305. PubMed ID: 35247922
[TBL] [Abstract][Full Text] [Related]
8. Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology.
Galle PR; Kudo M; Llovet JM; Finn RS; Karwal M; Pezet D; Kim TY; Yang TS; Lonardi S; Tomasek J; Phelip JM; Touchefeu Y; Koh SJ; Stirnimann G; Liang K; Ogburn KD; Wang C; Abada P; Widau RC; Zhu AX
Liver Int; 2021 Nov; 41(11):2759-2767. PubMed ID: 34173317
[TBL] [Abstract][Full Text] [Related]
9. Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2.
Finn RS; Yau T; Hsu CH; De Toni EN; Goyal L; Galle PR; Qin S; Rao S; Sun F; Wang C; Widau RC; Zhu AX
Oncologist; 2022 Dec; 27(12):e938-e948. PubMed ID: 36190331
[TBL] [Abstract][Full Text] [Related]
10. Ramucirumab: A Review in Hepatocellular Carcinoma.
Syed YY
Drugs; 2020 Feb; 80(3):315-322. PubMed ID: 32034692
[TBL] [Abstract][Full Text] [Related]
11. Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2).
Kudo M; Finn RS; Morimoto M; Rau KM; Ikeda M; Yen CJ; Galle PR; Llovet JM; Daniele B; Lim HY; McIlwain DW; Yoshikawa R; Nakamura K; Liang K; Wang C; Abada P; Widau RC; Zhu AX
Liver Cancer; 2021 Sep; 10(5):451-460. PubMed ID: 34721507
[TBL] [Abstract][Full Text] [Related]
12. Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab.
Zhu AX; Finn RS; Kang YK; Yen CJ; Galle PR; Llovet JM; Assenat E; Brandi G; Motomura K; Ohno I; Daniele B; Vogel A; Yamashita T; Hsu CH; Gerken G; Bilbruck J; Hsu Y; Liang K; Widau RC; Wang C; Abada P; Kudo M
Br J Cancer; 2021 Apr; 124(8):1388-1397. PubMed ID: 33531690
[TBL] [Abstract][Full Text] [Related]
13. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial.
Kudo M; Hatano E; Ohkawa S; Fujii H; Masumoto A; Furuse J; Wada Y; Ishii H; Obi S; Kaneko S; Kawazoe S; Yokosuka O; Ikeda M; Ukai K; Morita S; Tsuji A; Kudo T; Shimada M; Osaki Y; Tateishi R; Sugiyama G; Abada PB; Yang L; Okusaka T; Zhu AX
J Gastroenterol; 2017 Apr; 52(4):494-503. PubMed ID: 27549242
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Ramucirumab
Maesaka K; Sakamori R; Yamada R; Tahata Y; Ohkawa K; Oshita M; Tamura S; Hagiwara H; Mita E; Yakushijin T; Inada M; Kodama T; Hikita H; Tatsumi T; Takehara T
Anticancer Res; 2021 Apr; 41(4):2187-2192. PubMed ID: 33813432
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of ramucirumab treatment for patients with hepatocellular carcinoma who progressed on sorafenib with α-fetoprotein concentrations of at least 400 ng/ml.
Zheng H; Qin Z; Qiu X; Zhan M; Wen F; Xu T
J Med Econ; 2020 Apr; 23(4):347-352. PubMed ID: 31856618
[No Abstract] [Full Text] [Related]
16. Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2.
Kudo M; Galle PR; Brandi G; Kang YK; Yen CJ; Finn RS; Llovet JM; Assenat E; Merle P; Chan SL; Palmer DH; Ikeda M; Yamashita T; Vogel A; Huang YH; Abada PB; Yoshikawa R; Shinozaki K; Wang C; Widau RC; Zhu AX
JHEP Rep; 2021 Apr; 3(2):100215. PubMed ID: 33392490
[TBL] [Abstract][Full Text] [Related]
17. Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab.
Reig M; Galle PR; Kudo M; Finn R; Llovet JM; Metti AL; Schelman WR; Liang K; Wang C; Widau RC; Abada P; Zhu AX
Liver Int; 2021 Mar; 41(3):598-607. PubMed ID: 33188713
[TBL] [Abstract][Full Text] [Related]
18. Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study.
Chau I; Park JO; Ryoo BY; Yen CJ; Poon R; Pastorelli D; Blanc JF; Kudo M; Pfiffer T; Hatano E; Chung HC; Kopeckova K; Phelip JM; Brandi G; Ohkawa S; Li CP; Okusaka T; Hsu Y; Abada PB; Zhu AX
Br J Cancer; 2018 Jul; 119(1):19-26. PubMed ID: 29808014
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.
Bruix J; Cheng AL; Meinhardt G; Nakajima K; De Sanctis Y; Llovet J
J Hepatol; 2017 Nov; 67(5):999-1008. PubMed ID: 28687477
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis.
Chen J; Wang J; Xie F
Medicine (Baltimore); 2021 Sep; 100(38):e27013. PubMed ID: 34559096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
